By Scientific Affairs Team, Signios

The road from protein biomarker discovery to clinical utility is rarely straight. Researchers routinely identify candidate proteins in discovery-phase experiments, only to watch those signals fail to replicate under the rigorous quantitative conditions required for translational validation.

Closing that gap demands not only scientific rigor, but the right proteomics infrastructure—one capable of delivering both depth and reproducibility across a broad dynamic range.

The Proteomics Gap in Translational Medicine

Despite the central role proteins play in disease biology, translational proteomics has historically lagged behind genomics in throughput and standardization. Early mass spectrometry workflows were powerful but low-throughput and difficult to standardize across sites. Many candidate biomarkers identified through shotgun proteomics never advanced, not because the biology was wrong, but because the measurement technology wasn’t reproducible enough to survive the journey to clinical validation.

Today, the landscape has shifted substantially. A new generation of quantitative proteomics platforms now offers the throughput, sensitivity, and inter-assay consistency needed to support both discovery and validation within a single integrated pipeline.

From Relative to Absolute: Quantification Strategies That Matter

A persistent challenge in translational proteomics is the distinction between relative and absolute protein quantification. Relative approaches—label-free quantification, TMT/iTRAQ labeling, and similar methods—excel at identifying differential expression across sample groups, making them ideal for hypothesis generation. However, they fall short when the goal is to establish clinically actionable thresholds or to compare results across cohorts and laboratories.

Absolute quantification strategies—including selected reaction monitoring (SRM), parallel reaction monitoring (PRM), and isotope-dilution mass spectrometry—anchor measurements to known concentrations, enabling direct comparisons between samples, timepoints, and study sites. For programs targeting regulatory submission or companion diagnostic development, the shift to absolute quantification is not optional; it is foundational.

Bridging Discovery and Validation with Olink Reveal

One platform that has gained significant traction in translational proteomics is the Olink proximity extension assay (PEA) technology. By pairing antibody-based protein detection with next-generation sequencing readouts, Olink delivers high specificity and a dynamic range that extends well into the low-abundance protein space—the very space where many disease-relevant biomarkers reside.

Signios Bio’s Olink Reveal service is purpose-built for this translational context. Rather than simply running panels, Signios applies Olink technology within a structured workflow designed to support downstream validation: from panel selection and sample preparation guidance, through QC-controlled data generation, to normalized protein expression output that integrates directly with statistical modeling and multiomic datasets. This end-to-end approach reduces the attrition that typically occurs when discovery data is handed off to a separate validation lab working with a different platform.

Integrating Proteomics into Multiomics Workflows

Biomarker programs increasingly rely on the convergence of multiple molecular layers. A protein biomarker that co-varies with a specific transcriptomic signature or somatic mutation carries substantially greater translational weight than a protein signal interpreted in isolation. Achieving this level of molecular context requires a CRO capable of executing across modalities under a unified quality framework.

Signios Bio is uniquely positioned to support this integrated approach. With services spanning spatial transcriptomics (10X Xenium and Visium), bulk NGS, long read sequencing, and proteomics (Olink Reveal), researchers can generate spatially resolved gene expression data alongside high-plex protein quantification from the same tissue or biofluid samples. This co-registration of data layers enables the kind of systems-level insight that is increasingly expected by translational reviewers and scientific advisory boards.

Partnering for Translational Success

Translational research timelines are unforgiving. Delays in sample processing, inconsistent QC, or platform mismatches between discovery and validation phases can set a program back by months. Choosing a proteomics partner with deep platform expertise, rigorous data standards, and a multiomics infrastructure is not a vendor decision—it is a scientific strategy decision.

Signios Bio was built around this reality. By combining validated quantitative proteomics workflows with spatial genomics capabilities and an NGS backbone, Signios provides the molecular breadth and translational depth that modern biomarker programs demand. Whether your program is in early discovery or actively advancing toward a clinical validation study, Signios Bio offers the integrated services and scientific partnership to move your biomarker pipeline forward with confidence.

Ready to accelerate your biomarker program? Explore Signios Bio’s quantitative proteomics services to learn how we can support your translational research goals.